Viagra

RSS

sildenafil

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Viagra. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Viagra.

This EPAR was last updated on 17/03/2023

Authorisation details

Product details
Name
Viagra
Agency product number
EMEA/H/C/000202
Active substance
sildenafil
International non-proprietary name (INN) or common name
sildenafil
Therapeutic area (MeSH)
Erectile Dysfunction
Anatomical therapeutic chemical (ATC) code
G04BE03
Publication details
Marketing-authorisation holder
Upjohn EESV
Revision
44
Date of issue of marketing authorisation valid throughout the European Union
13/09/1998
Contact address

Rivium Westlaan 142 
Capelle aan den Ijssel
2909 LD
Netherlands

Product information

14/03/2023 Viagra - EMEA/H/C/000202 - N/0117

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

In order for Viagra to be effective, sexual stimulation is required.

Assessment history

Related content

How useful was this page?

Add your rating
Average
20 ratings
22 ratings
25 ratings
14 ratings